Studies using new approaches and alternative treatments that address the most optimal medications for co-occurring conditions such as gestational diabetes, metabolic syndrome, depression, disordered sleep, NALFD, dyslipidemia, among others, are needed to expand options for persons with PCOS. Additional knowledge gaps exist in how various therapies affect gynecologic, reproductive, and obstetrical sequelae of PCOS. Research addressing these knowledge gaps could yield safer and more effective treatments for various presentations of PCOS, leading to paradigm changes and scientific advances in individualized and precision therapy for adolescents and adults with PCOS.

Specific areas of interest include, but are not limited to, the following examples:

• Studies to investigate effects of therapies of specific comorbid conditions on gynecologic, reproductive and/or obstetrical outcomes occurring in persons with PCOS.
• Studies of the safety and efficacy of specific treatments addressing comorbid conditions (obesity, insulin resistance, anxiety, depression, sleep disorders, sleep disordered breathing, hyperandrogenism, endometrial hyperplasia, among others) that do not preclude pregnancy or breast-feeding in persons with PCOS.
• Discovery of novel treatments of various components of metabolic syndrome in women with PCOS that have beneficial or non-deleterious impact on gynecologic, reproductive, obstetrical and perinatal outcomes.
• Studies to identify pharmacologic treatments for anxiety and/or depression in adolescents and women with PCOS, including in the postpartum period, that do not interfere with fecundability, sexual function, obstetrical outcomes, and are safe in lactating women.
• Studies investigating how treatments for PCOS affect the development of or risk for comorbid conditions, as well as studies investigating adjuvants used in conjunction with therapies to stimulate ovulation will not be considered responsive.